Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/103324
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukaemia
Author: Banjar, H.
Ranasinghe, D.
Brown, F.
Adelson, D.
Kroger, T.
Leclercq, T.
White, D.
Hughes, T.
Chaudhri, N.
Citation: PLoS One, 2017; 12(1):1-23
Publisher: PloSOne
Issue Date: 2017
ISSN: 1932-6203
1932-6203
Editor: Speletas, M.
Statement of
Responsibility: 
Haneen Banjar, Damith Ranasinghe, Fred Brown, David Adelson, Trent Kroger, Tamara Leclercq, Deborah White, Timothy Hughes, Naeem Chaudhri
Abstract: BACKGROUND: Treatment of patients with chronic myeloid leukaemia (CML) has become increasingly difficult in recent years due to the variety of treatment options available and challenge deciding on the most appropriate treatment strategy for an individual patient. To facilitate the treatment strategy decision, disease assessment should involve molecular response to initial treatment for an individual patient. Patients predicted not to achieve major molecular response (MMR) at 24 months to frontline imatinib may be better treated with alternative frontline therapies, such as nilotinib or dasatinib. The aims of this study were to i) understand the clinical prediction 'rules' for predicting MMR at 24 months for CML patients treated with imatinib using clinical, molecular, and cell count observations (predictive factors collected at diagnosis and categorised based on available knowledge) and ii) develop a predictive model for CML treatment management. This predictive model was developed, based on CML patients undergoing imatinib therapy enrolled in the TIDEL II clinical trial with an experimentally identified achieving MMR group and non-achieving MMR group, by addressing the challenge as a machine learning problem. The recommended model was validated externally using an independent data set from King Faisal Specialist Hospital and Research Centre, Saudi Arabia. PRINCIPLE FINDINGS: The common prognostic scores yielded similar sensitivity performance in testing and validation datasets and are therefore good predictors of the positive group. The G-mean and F-score values in our models outperformed the common prognostic scores in testing and validation datasets and are therefore good predictors for both the positive and negative groups. Furthermore, a high PPV above 65% indicated that our models are appropriate for making decisions at diagnosis and pre-therapy. Study limitations include that prior knowledge may change based on varying expert opinions; hence, representing the category boundaries of each predictive factor could dramatically change performance of the models.
Keywords: Humans
Pyrimidines
Antineoplastic Agents
Treatment Outcome
Cell Count
Cohort Studies
Predictive Value of Tests
Inhibitory Concentration 50
Algorithms
Models, Theoretical
Adolescent
Adult
Aged
Aged, 80 and over
Middle Aged
Saudi Arabia
Female
Male
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Young Adult
Kaplan-Meier Estimate
Machine Learning
Imatinib Mesylate
Dasatinib
Rights: © 2017 Banjar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI: 10.1371/journal.pone.0168947
Published version: http://dx.doi.org/10.1371/journal.pone.0168947
Appears in Collections:Aurora harvest 3
Genetics publications

Files in This Item:
File Description SizeFormat 
hdl_103324.pdfPublished version2.47 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.